Featured Publications
Neoantigens in Patients with De Novo Follicular Lymphoma: Results from the PRIMA Study
Henneges C, Jin D, Venstrom J, Trabucco S, Nielsen T, Penuel E, Huet S, Salles G, Paulson J. Neoantigens in Patients with De Novo Follicular Lymphoma: Results from the PRIMA Study. Blood 2020, 136: 25-26. DOI: 10.1182/blood-2020-134795.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaDe novo diffuse large B-cell lymphomaProgression-free survivalTumor mutational burdenComprehensive genomic profilingCurrent equity holderAssociated with progression-free survivalFollicular lymphomaF. Hoffmann-La RocheFoundation MedicinePrognostic valueClinical outcomesMedian tumor mutation burdenProgression-free survival eventsPooled analysis of patientsLarge B-cell lymphomaResponse to induction treatmentCalculate tumor mutational burdenAssociated with clinical outcomesEZH2 mutation statusComprehensive genomic profiling dataB-cell lymphomaGenetic mutational landscapeAnalysis of patientsProportion of patients
2022
Patient‐reported outcomes provide prognostic information for survival in patients with diffuse large B‐cell lymphoma: Analysis of 1239 patients from the GOYA study
Huang H, Datye A, Fan M, Knapp A, Nielsen T, Bottos A, Paulson J, Trask P, Efficace F. Patient‐reported outcomes provide prognostic information for survival in patients with diffuse large B‐cell lymphoma: Analysis of 1239 patients from the GOYA study. Cancer Medicine 2022, 11: 3312-3322. PMID: 35322932, PMCID: PMC9468432, DOI: 10.1002/cam4.4692.Peer-Reviewed Original ResearchConceptsDiffuse large B-cell lymphomaInternational Prognostic IndexProgression-free survivalLarge B-cell lymphomaB-cell lymphomaOverall survivalPrognostic valuePatient-reported outcomesPrognostic informationCox regression analysis of overall survivalClinical variablesAnalysis of overall survivalPhase III studyFifty-nine patientsCox regression analysisPatient risk stratificationPopulation of patientsEuropean Organization for Research and Treatment of Cancer Quality of LifeEuropean Organization for Research and TreatmentPlus chemotherapyIII studiesPrognostic indexTreatment of Cancer Quality of LifeGlobal health status/quality of lifeGlobal health status/quality
2020
Automated Baseline Fluorodeoxyglucose-Positron Emission Tomography Imaging and High BCL2 Expression Provide Orthogonal Prognostic Value in Predicting High-Risk De Novo Diffuse Large B-Cell Lymphoma Patients
Jemaa S, Tracy S, Bottos A, de Crespigny A, Bengtsson T, Nielsen T, Paulson J. Automated Baseline Fluorodeoxyglucose-Positron Emission Tomography Imaging and High BCL2 Expression Provide Orthogonal Prognostic Value in Predicting High-Risk De Novo Diffuse Large B-Cell Lymphoma Patients. Blood 2020, 136: 8-9. DOI: 10.1182/blood-2020-134780.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaDiffuse large B-cell lymphoma patientsCurrent equity holderInternational Prognostic IndexTotal metabolic tumor volumeFluorodeoxyglucose-positron emission tomographyF Hoffmann-La RocheArea under the receiver operating characteristic curveR-CHOPPrognostic valueClinical featuresFluorodeoxyglucose-positron emission tomography imagingBCL2 expressionAssociated with reduced PFSInternational Prognostic Index categoryPrognostic value of Bcl2F. Hoffmann-La RocheB-cell lymphoma patientsLarge B-cell lymphomaCell of origin (COOMultivariable Cox-pH modelsPrognostic modelUnivariate Cox proportional hazardsBaseline imaging featuresMetabolic tumor volumeAbstract 2035: Listen to the patients: Assessing the prognostic value of pre-treatment health-related quality of life in 1L DLBCL patients
Huang H, Datye A, Fan M, Knapp A, Balakrishnan R, Balasubramanian S, Chae J, Roth E, Nielsen T, Paulson J, Trask P. Abstract 2035: Listen to the patients: Assessing the prognostic value of pre-treatment health-related quality of life in 1L DLBCL patients. Cancer Research 2020, 80: 2035-2035. DOI: 10.1158/1538-7445.am2020-2035.Peer-Reviewed Original ResearchDiffuse large B-cell lymphoma patientsDiffuse large B-cell lymphomaInternational Prognostic IndexProgression free survivalPre-treatment HRQOLPrognostic valueOverall survivalHealth-related quality of lifePatient-reported health-related quality-of-lifeAssociated with better survival outcomesLarge B-cell lymphomaHigh risk of progressionQuality of lifeAnn Arbor stageB-cell lymphomaBetter survival outcomesKaplan-Meier methodAmerican Association for Cancer ResearchContribution to prognosisImprove risk stratificationCox proportional hazards modelsNovel treatment strategiesHRQOL subscale scoresStatus of patientsInformed treatment decisions